Bal Pharma Limited (BALPHARMA) - Net Assets
Based on the latest financial reports, Bal Pharma Limited (BALPHARMA) has net assets worth Rs822.52 Million INR (≈ $8.90 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Rs3.76 Billion ≈ $40.61 Million USD) and total liabilities (Rs2.93 Billion ≈ $31.72 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Bal Pharma Limited (BALPHARMA) tangible net worth to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Rs822.52 Million |
| % of Total Assets | 21.9% |
| Annual Growth Rate | 4.78% |
| 5-Year Change | 40.62% |
| 10-Year Change | 37.02% |
| Growth Volatility | 8.65 |
Bal Pharma Limited - Net Assets Trend (2006–2026)
This chart illustrates how Bal Pharma Limited's net assets have evolved over time, based on quarterly financial data. See BALPHARMA defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Bal Pharma Limited (2006–2026)
The table below shows the annual net assets of Bal Pharma Limited from 2006 to 2026. For live valuation and market cap data, see Bal Pharma Limited (BALPHARMA) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2026-03-31 | Rs822.52 Million ≈ $8.90 Million |
+6.26% |
| 2025-03-31 | Rs774.04 Million ≈ $8.37 Million |
+11.76% |
| 2024-03-31 | Rs692.61 Million ≈ $7.49 Million |
+8.73% |
| 2023-03-31 | Rs637.02 Million ≈ $6.89 Million |
+8.91% |
| 2022-03-31 | Rs584.92 Million ≈ $6.33 Million |
+9.63% |
| 2021-03-31 | Rs533.54 Million ≈ $5.77 Million |
+17.68% |
| 2020-03-31 | Rs453.38 Million ≈ $4.90 Million |
-24.71% |
| 2019-03-31 | Rs602.21 Million ≈ $6.51 Million |
+0.03% |
| 2018-03-31 | Rs602.01 Million ≈ $6.51 Million |
+0.28% |
| 2017-03-31 | Rs600.31 Million ≈ $6.49 Million |
+9.70% |
| 2016-03-31 | Rs547.22 Million ≈ $5.92 Million |
-0.81% |
| 2015-03-31 | Rs551.68 Million ≈ $5.97 Million |
+10.23% |
| 2014-03-31 | Rs500.50 Million ≈ $5.41 Million |
+12.17% |
| 2013-03-31 | Rs446.18 Million ≈ $4.83 Million |
+11.39% |
| 2012-03-31 | Rs400.56 Million ≈ $4.33 Million |
+10.73% |
| 2011-03-31 | Rs361.75 Million ≈ $3.91 Million |
+1.16% |
| 2010-03-31 | Rs357.62 Million ≈ $3.87 Million |
-3.95% |
| 2009-03-31 | Rs372.35 Million ≈ $4.03 Million |
+6.29% |
| 2008-03-31 | Rs350.32 Million ≈ $3.79 Million |
+4.88% |
| 2007-03-31 | Rs334.02 Million ≈ $3.61 Million |
+3.41% |
| 2006-03-31 | Rs323.02 Million ≈ $3.49 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Bal Pharma Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 0.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (March 2026)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Rs159.21 Million | 19.36% |
| Other Components | Rs663.07 Million | 80.64% |
| Total Equity | Rs822.27 Million | 100.00% |
Bal Pharma Limited Competitors by Market Cap
The table below lists competitors of Bal Pharma Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Viver Incorporadora e Construtora S.A
SA:VIVR3
|
$15.13 Million |
|
Raptis Group Ltd
AU:RPG
|
$15.14 Million |
|
KineMaster Corporation
KQ:139670
|
$15.14 Million |
|
De.Mem Ltd
AU:DEM
|
$15.14 Million |
|
Aegis Brands Inc
TO:AEG
|
$15.12 Million |
|
Ohmyhome Limited Ordinary Shares
NASDAQ:OMH
|
$15.11 Million |
|
MOGU Inc
NYSE:MOGU
|
$15.11 Million |
|
Gale Pacific Ltd
AU:GAP
|
$15.10 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Bal Pharma Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2025 to 2026, total equity changed from 774,159,000 to 822,274,000, a change of 48,115,000 (6.2%).
- Net income of 62,835,000 contributed positively to equity growth.
- Dividend payments of 19,105,000 reduced retained earnings.
- Share repurchases of 1,000 reduced equity.
- Other comprehensive income decreased equity by 22,067,000.
- Other factors increased equity by 26,453,000.
Equity Change Factors (2025 to 2026)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Rs62.84 Million | +7.64% |
| Dividends Paid | Rs19.11 Million | -2.32% |
| Share Repurchases | Rs1.00K | -0.0% |
| Other Comprehensive Income | Rs-22.07 Million | -2.68% |
| Other Changes | Rs26.45 Million | +3.22% |
| Total Change | Rs- | 6.22% |
Book Value vs Market Value Analysis
This analysis compares Bal Pharma Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.70x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 2.72x to 1.70x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2006-03-31 | Rs32.31 | Rs87.79 | x |
| 2007-03-31 | Rs31.98 | Rs87.79 | x |
| 2008-03-31 | Rs32.63 | Rs87.79 | x |
| 2009-03-31 | Rs35.30 | Rs87.79 | x |
| 2010-03-31 | Rs33.97 | Rs87.79 | x |
| 2011-03-31 | Rs34.35 | Rs87.79 | x |
| 2012-03-31 | Rs38.04 | Rs87.79 | x |
| 2013-03-31 | Rs42.20 | Rs87.79 | x |
| 2014-03-31 | Rs45.43 | Rs87.79 | x |
| 2015-03-31 | Rs42.61 | Rs87.79 | x |
| 2016-03-31 | Rs42.65 | Rs87.79 | x |
| 2017-03-31 | Rs44.44 | Rs87.79 | x |
| 2018-03-31 | Rs45.86 | Rs87.79 | x |
| 2019-03-31 | Rs47.02 | Rs87.79 | x |
| 2020-03-31 | Rs36.99 | Rs87.79 | x |
| 2021-03-31 | Rs37.74 | Rs87.79 | x |
| 2022-03-31 | Rs38.72 | Rs87.79 | x |
| 2023-03-31 | Rs40.66 | Rs87.79 | x |
| 2024-03-31 | Rs43.84 | Rs87.79 | x |
| 2025-03-31 | Rs53.09 | Rs87.79 | x |
| 2026-03-31 | Rs51.69 | Rs87.79 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Bal Pharma Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 7.64%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 2.02%
- • Asset Turnover: 0.83x
- • Equity Multiplier: 4.57x
- Recent ROE (7.64%) is above the historical average (5.14%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2006 | 10.34% | 4.99% | 0.76x | 2.73x | Rs1.10 Million |
| 2007 | 6.04% | 2.87% | 0.78x | 2.71x | Rs-13.23 Million |
| 2008 | 8.16% | 3.33% | 0.79x | 3.11x | Rs-6.46 Million |
| 2009 | 8.04% | 2.89% | 0.85x | 3.26x | Rs-7.31 Million |
| 2010 | -4.00% | -1.35% | 0.86x | 3.47x | Rs-50.05 Million |
| 2011 | 1.13% | 0.36% | 0.84x | 3.74x | Rs-32.10 Million |
| 2012 | 9.38% | 2.69% | 0.99x | 3.52x | Rs-2.49 Million |
| 2013 | 9.60% | 2.90% | 0.99x | 3.36x | Rs-1.78 Million |
| 2014 | 10.13% | 2.84% | 1.16x | 3.09x | Rs673.43K |
| 2015 | 6.57% | 1.94% | 1.14x | 2.97x | Rs-18.92 Million |
| 2016 | 2.56% | 0.71% | 0.94x | 3.84x | Rs-40.85 Million |
| 2017 | 3.15% | 0.87% | 0.99x | 3.66x | Rs-43.13 Million |
| 2018 | 4.28% | 1.33% | 0.83x | 3.87x | Rs-37.17 Million |
| 2019 | 5.68% | 1.68% | 0.86x | 3.92x | Rs-28.76 Million |
| 2020 | -23.31% | -7.14% | 0.72x | 4.55x | Rs-174.61 Million |
| 2021 | 8.85% | 1.92% | 1.03x | 4.48x | Rs-6.16 Million |
| 2022 | 9.57% | 2.00% | 1.08x | 4.44x | Rs-2.51 Million |
| 2023 | 4.03% | 0.85% | 0.97x | 4.91x | Rs-38.07 Million |
| 2024 | 10.67% | 2.18% | 1.06x | 4.61x | Rs4.63 Million |
| 2025 | 9.32% | 2.38% | 0.90x | 4.34x | Rs-5.26 Million |
| 2026 | 7.64% | 2.02% | 0.83x | 4.57x | Rs-19.39 Million |
Industry Comparison
This section compares Bal Pharma Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $41,118,163,484
- Average return on equity (ROE) among peers: 13.86%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Bal Pharma Limited (BALPHARMA) | Rs822.52 Million | 10.34% | 3.57x | $15.12 Million |
| Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS) | $366.97 Million | 3.51% | 2.41x | $25.11 Million |
| Aarti Drugs Limited (AARTIDRUGS) | $1.23 Billion | 12.93% | 2.27x | $365.36 Million |
| Aarti Pharmalabs Limited (AARTIPHARM) | $2.31 Million | -8.08% | 0.08x | $645.54 Million |
| Abbott India Limited (ABBOTINDIA) | $2.31 Billion | 29.62% | 0.43x | $6.01 Billion |
| Ajanta Pharma Limited (AJANTPHARM) | $32.64 Billion | 21.83% | 0.24x | $4.15 Billion |
| Akums Drugs and Pharmaceutical (AKUMS) | $7.23 Billion | 13.11% | 3.52x | $996.26 Million |
| Alkem Laboratories Limited (ALKEM) | $75.58 Billion | 20.97% | 0.52x | $6.95 Billion |
| Amrutanjan Health Care Limited (AMRUTANJAN) | $1.09 Billion | 18.92% | 0.29x | $170.62 Million |
| Alembic Pharmaceuticals Limited (APLLTD) | $22.20 Billion | 18.58% | 0.77x | $1.59 Billion |
| Aurobindo Pharma Limited (AUROPHARMA) | $268.52 Billion | 7.18% | 0.49x | $8.98 Billion |
About Bal Pharma Limited
Bal Pharma Limited, together with its subsidiaries, manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers prescription drugs, generics, OTC products, intravenous infusion products, and bulk drugs. It also provides anti-infectives, pain management, respiratory care, and women's health products under the Az… Read more